.jpg)
Bharat Biotech has developed the iNCOVACC nasal vaccine against COVID-19, with the capacity to manufacture over 10 million doses, according to Sai Prasad, President of Quality Operations at Bharat Biotech. Speaking at BioAsia, a life sciences and healthcare event in Telangana, Prasad said that the company has already supplied over 300,000 doses of the nasal vaccine to the private sector. The vaccine can also be used as a booster and is designed to trigger an immune response in the nose and upper airway, which blocks infection and breaks the chain of transmission. Despite being a late entrant to the COVID-19 vaccine market, the nasal vaccine is priced at INR 800 per dose in private markets and INR 325 per dose for government procurement. The government has not placed any orders for the vaccine, according to the union ministry of health and family welfare.
